Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by NEOS Investment Management LLC

NEOS Investment Management LLC boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,962 shares of the medical equipment provider’s stock after acquiring an additional 779 shares during the period. NEOS Investment Management LLC’s holdings in Lantheus were worth $712,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. State of New Jersey Common Pension Fund D increased its position in Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after buying an additional 115 shares in the last quarter. Bleakley Financial Group LLC raised its position in shares of Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after buying an additional 129 shares during the last quarter. Avantax Advisory Services Inc. lifted its stake in shares of Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after buying an additional 132 shares during the period. UMB Bank n.a. boosted its position in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares during the last quarter. Finally, Aurora Investment Counsel grew its stake in Lantheus by 0.8% in the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider’s stock worth $1,718,000 after acquiring an additional 146 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Stock Down 0.9 %

Shares of LNTH stock opened at $96.16 on Monday. Lantheus Holdings, Inc. has a fifty-two week low of $58.16 and a fifty-two week high of $126.89. The firm’s 50 day moving average price is $93.21 and its two-hundred day moving average price is $96.38. The stock has a market cap of $6.59 billion, a price-to-earnings ratio of 16.00 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LNTH. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, B. Riley dropped their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.